Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Find Serenity: 10 Stunning Setting up camp Areas - 2Dental Embed Developments: Upsetting Current Dentistry
- 36 U.S. States for Climbing
- 4Figure out How to Explore Your Direction to the Best Dental Embed Trained professional: A Far reaching Manual
- 5Norovirus infections increase significantly, with positive test rates reaching 14%
- Kids get diseases like lupus, too. As researchers hunt better treatments, this camp brings joy
- 4 DSLR Cameras for Amateurs in 2024
- Hamas set to elect new terror leader with Hayya, Mashaal in pole position
- Ancient eggshells shed new light on crocodiles that hunted prey from trees
- Artemis will take Americans to the moon for the 1st time since 1972. Why has it been so hard to go back?
- Noctourism: the new safari travel trend that's changing the wildlife we can photograph in Africa
- Rebecca Gayheart on her 'very complicated' relationship with Eric Dane: 'I am always going to want the best for him'
- How to identify animal tracks, burrows and other signs of wildlife in your neighborhood
- Plane Passenger Allegedly Includes ‘Bomb Threat’ in Hotspot Network Name, Forces Flight to Make Emergency Landing
